montelukast / Generic mfg. - LARVOL DELTA

Evaluation of infusion related reactions with obinutuzumab in chronic lymphocytic leukemia (CLL) patients receiving montelukast pre-medication (HOPA 2026) - "Background/Rationale: Obinutuzumab, a glycoengineered anti-CD20 monoclonal antibody, is associated with a high incidence of infusion-related reactions (IRRs), particularly during the first infusion, with higher rates of severe (grade > 3) reactions compared with rituximab. Conclusions will be determined upon completion of data analysis."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma

Montelukast and Delirium Risk During Intensive Care Unit (ICU) Stay: Findings from a Cohort Study. (PubMed, Clin Pharmacol) - "Our study demonstrates an association between montelukast use during ICU admission and a higher incidence of delirium. Prospective randomized studies are needed to confirm these findings."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Critical care • Psychiatry • Renal Disease • Respiratory Diseases

Montelukast impressively mitigates biomarkers of inflammation in non-ST-segment elevation myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The findings highlighted that Montelukast may mitigate inflammatory indicators, namely, hs-CRP and IL-6, and could be considered for NSTEMI patients. Otherwise, more clinical trials are required to determine its effectiveness in clinical administration."

Biomarker • Clinical • Journal • Cardiovascular • Inflammation • Myocardial Infarction • CRP • IL6

Effect of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptor antagonist, in guinea pig models of allergic rhinitis. (PubMed, J Pharmacol Sci) - "Subsequently, in a model with S-hexyl GSH treatment to inhibit LTC4 metabolism and enhance CysLT2 receptor-mediated responses, ONO-6950 (0.3, 1, or 3 mg/kg, p.o.) dose-dependently and almost completely inhibited both immediate and late increases in nasal airway resistance and inflammatory cell infiltration, whereas montelukast showed only partial or negligible inhibition. These results indicate that ONO-6950 is effective against both CysLT1-and CysLT2-mediated rhinitic responses, and may offer a novel therapeutic option for patients with allergic rhinitis, particularly in cases refractory to CysLT1-selective antagonists."

Journal • Preclinical • Allergic Rhinitis • Immunology • Inflammation • CYSLTR2

Eco-friendly RP-HPLC determination of bambuterol hydrochloride and montelukast sodium in tablet dosage with dissolution analysis. (PubMed, Sci Rep) - "Overall, the method offers a robust, greener alternative for routine assay and dissolution testing of BBL and MTK in pharmaceuticals. The online version contains supplementary material available at 10.1038/s41598-026-41125-x."

Journal

Gut microbiome in long COVID patients: exploring the role of montelukast (ESCMID Global 2026) - No abstract available

Clinical • Novel Coronavirus Disease

Montelukast for asthmatic children: to give or not to give (EAACI 2026) - No abstract available

Clinical • Immunology

A real world retrospective study to evaluate the effectiveness & safety of montelukast & fexofenadine FDC in the management of patients with allergic rhinitis (EAACI 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Allergic Rhinitis • Immunology • Inflammation

Neuropsychiatric events associated with montelukast in children: a systematic review (EAACI 2026) - No abstract available

Clinical • Review • Immunology

Pharmacokinetic-guided optimization of weight-based dosing for high dose oral montelukast in children with acute asthma exacerbations (PAS 2026) - No abstract available

Clinical • PK/PD data • Asthma • Immunology • Respiratory Diseases

Cardiac Arrest in a Healthy Child: Unmasking Long QT Syndrome Following Pantoprazole Exposure (SCCM 2026) - "This case highlights a rare but serious pediatric cardiac arrest revealing latent LQTS after pantoprazole exposureDescription: A previously healthy 3-year-old male with mild asthma (on montelukast) was admitted for viral gastroenteritis with moderate dehydration...He was intubated and transferred to the PICU, where he remained on epinephrine infusion for 24 hours.EEG showed diffuse reactive slowing; brain MRI was unremarkable...Serial ECGs and family screening were crucial for diagnosis.Clinicians should maintain vigilance regarding QT-prolonging agents, particularly in pediatric patients with unexplained events or concerning family history. Early recognition and multidisciplinary management enabled a favorable outcome in this high-risk case"

Clinical • Asthma • Cardiovascular • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Respiratory Diseases

CORONARY ARTERY BYPASS GRAFTING IN COLD-INDUCED URTICARIA USING PREMEDICATION AND STRICT THERMAL MANAGEMENT: A CASE REPORT (ACC 2026) - "Premedication included fexofenadine, cetirizine, famotidine, montelukast, prednisolone, and diphenhydramine. Omalizumab was administered preoperatively. Epinephrine pen was available during the procedure... CABG can be safely accomplished in patients with cold-induced urticaria by combining structured premedication with vigilant thermal control. This case adds intraoperative temperature and cardioplegia parameters demonstrating safe on-pump CABG with moderate systemic cooling, cold cardioplegia, and elimination of topical ice, supported by structured premedication."

Case report • Clinical • Cardiovascular • Dermatology • Dyslipidemia • Hypertension • Hypotension • Immunology • Nicotine Addiction • Peripheral Arterial Disease • Urticaria

Montelukast in Parkinson Disease (clinicaltrials.gov) - P2/3 | N=60 | Recruiting | Sponsor: Mostafa Bahaa | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Nov 2024 ➔ Nov 2026

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

CLINICAL CHARACTERISTICS AND TREATMENT RESPONSE OF NON-INFECTIOUS PULMONARY COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS (EBMT 2026) - "Commonly used drugs included calcineurin inhibitors (tacrolimus/cyclosporine), corticosteroids, JAK inhibitors (e.g., ruxolitinib), and components of the "FAM" regimen (fluticasone, azithromycin, montelukast). NIPCs following HSCT are a significant complication affecting long-term quality of life. Their clinical presentation is often nonspecific and coexists with chronic GVHD in other organs. Exertional dyspnea is a core symptom, while obstructive patterns on PFTs and air trapping on CT are key diagnostic clues."

Retrospective data • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cough • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Pulmonary Disease • Respiratory Diseases • Transplantation

MANAGEMENT OF SEVERE PULMONARY COMPLICATIONS FOLLOWING HSCT IN A PATIENT WITH Β-THALASSEMIA: A CASE REPORT ON SUCCESSFUL TREATMENT OF CMV PNEUMONIA, DAH, AND BOS (EBMT 2026) - "She underwent a matched unrelated donor (9/10 HLA-matched) allo-HSCT following a myeloablative conditioning regimen (fludarabine, busulfan, cyclophosphamide, ATG). GVHD prophylaxis included tacrolimus, methotrexate, mycophenolate mofetil, and pre-emptive infusions of umbilical cord-derived mesenchymal stromal cells (UC-MSCs)...The early post-transplant course was complicated by steroid-refractory, grade III acute GVHD (skin and gut), which was successfully managed with a second-line regimen of ruxolitinib, CD25 monoclonal antibody, budesonide, and additional UC-MSCs...Initial anti-CMV therapy (acyclovir/foscarnet) failed, indicating a refractory infection...Treatment with the FAM regimen (fluticasone, azithromycin, montelukast) combined with further cycles of UC-MSCs resulted in significant clinical and radiological improvement by day +220... This complex case illustrates the cascade of severe complications—refractory aGVHD, life-threatening CMV pneumonia with DAH, and..."

Case report • Clinical • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

CLINICAL CHARACTERISTICS AND TREATMENT RESPONSE OF NON-INFECTIOUS PULMONARY COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS (EBMT 2026) - "Commonly used drugs included calcineurin inhibitors (tacrolimus/cyclosporine), corticosteroids, JAK inhibitors (e.g., ruxolitinib), and components of the "FAM" regimen (fluticasone, azithromycin, montelukast). NIPCs following HSCT are a significant complication affecting long-term quality of life. Their clinical presentation is often nonspecific and coexists with chronic GVHD in other organs. Exertional dyspnea is a core symptom, while obstructive patterns on PFTs and air trapping on CT are key diagnostic clues."

Retrospective data • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cough • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Pulmonary Disease • Respiratory Diseases • Transplantation

Asthma-alleviating effects of Poria cocos based on network pharmacology and gut microbiota (PubMed, Zhongguo Zhong Yao Za Zhi) - "Male Balb/c mice were randomly divided into normal, model, positive control(montelukast sodium, 1.5 mg·kg~(-1)), low-dose P. cocos(0.057 g·kg~(-1)), medium-dose P. cocos(0.114 g·kg~(-1)), and high-dose P. cocos(0.227 g·kg~(-1)) group...GM sequencing showed that P. cocos effectively alleviated dysbiosis induced by OVA sensitization, significantly downregulated Muribaculum intestinale and Alistipes inops, and correlation analysis revealed both were positively correlated with pro-inflammatory factors. Therefore, it is speculated that P. cocos restores intestinal microecological homeostasis by reducing levels of M. intestinale and A. inops, decreases pro-inflammatory factor production, blocks the inflammatory cascade, and thereby exerts its asthma-alleviating effects."

Journal • Asthma • Cough • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IFNG • IL10 • IL4

Daratumumab in STK11 Mutated NSCLC (clinicaltrials.gov) - P2 | N=8 | Completed | Sponsor: NYU Langone Health | Recruiting ➔ Completed | N=14 ➔ 8 | Trial completion date: Dec 2026 ➔ Nov 2025 | Trial primary completion date: May 2026 ➔ Nov 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • STK11

Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology. (PubMed, PLoS One) - "Our study revealed LTRAs could increase the risk of EGPA, and initially explored potential genes and mechanisms of LTRAs-induced EGPA. It is helpful for clinicians to be alerted to the risk of EGPA during LTRAs administration."

Journal • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Langerhans Cell Histiocytosis • Rare Diseases • Vasculitis • EDN1 • HMOX1 • KDR • OCLN • PACERR • PTGS2

Alpha-Gal Syndrome Managed With Omalizumab for Perioperative Optimization of Total Hip Arthroplasty: A Case Report. (PubMed, JBJS Case Connect) - "Perioperative management of AGS incorporated omalizumab injections, avoidance of high-risk medications and surgical materials containing mammalian derivatives, and pretreatment (corticosteroids, H1 and H2 antihistamines, montelukast). She tolerated hip arthroplasty without perioperative anaphylaxis or AGS symptoms by 4 months of follow-up. High-risk medications include propofol (may contain glycerol), analgesics (gelatin, magnesium stearate, lactose), and heparin (porcine, bovine)."

Journal • Allergy • Anesthesia • Immunology • Orthopedics • Pain

Montelukast Therapy is Associated with Reduced Rates of Manipulation under Anesthesia Following TKA (AAOS 2026) - "While montelukast has been explored in rat models as a treatment for arthrofibrosis, this is the first large claims study to our knowledge that explores its efficacy in preventing clinically relevant stiffness following TKA, with potential to reduce additional operations. A prospective, randomized controlled trial should follow this study prior to adoption in clinical practice."

Asthma • Immunology • Orthopedics • Respiratory Diseases

Modulation of the HMGB1/TLR4 Pathway by Montelukast in PTZ-Induced Epilepsy: Alleviating Neuroinflammatory Oxidative Stress and Seizure Severity. (PubMed, Int J Neurosci) - "Montelukast (MTK) was evaluated at three dose levels (5, 10, and 20 mg/kg, i.p.), while levetiracetam (30 mg/kg, i.p.) served as a standard comparator. Furthermore, montelukast significantly decreases pro-inflammatory cytokines, including interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), along with other mediators of neuroinflammation such as high-mobility group box-1 (HMGB1), transforming growth factor-β (TGF-β), matrix metalloproteinase-9 (MMP9), and toll-like receptor-4 (TLR-4).Histopathological analysis confirmed that administration of montelukast protected cortical and hippocampal integrity by reducing neuronal damage. Collectively, these findings suggest that montelukast exhibits anticonvulsant and neuroprotective potential in a PTZ model and supports further investigation in epilepsy."

Journal • CNS Disorders • Epilepsy • Inflammation • Oncology • CAT • HMGB1 • IL1B • IL6 • MMP9 • TGFB1 • TLR4 • TNFA

PRISM: PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia (clinicaltrials.gov) - P1/2 | N=28 | Recruiting | Sponsor: Duke University | Not yet recruiting ➔ Recruiting

Enrollment open • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

Eosinophilic gastroenteritis in a 45-year-old female with epigastric abdominal pain: a rare case report. (PubMed, Ann Med Surg (Lond)) - "Physicians should recognize EGE and its therapeutic complexities. Montelukast may serve as an effective corticosteroid-sparing strategy, enabling early symptom resolution and long-term remission."

Journal • Eosinophilia • Eosinophilic Esophagitis • Gastroenterology • Gastrointestinal Disorder • Pain

Improving the Quality of Care for Patients With CSU: Factors Affecting Resolution of CSU Symptoms (AAAAI 2026) - "For CSU symptoms ongoing, resolved, and unknown, the proportion of patients prescribed H2 blockers (29%, 43%, 46%, P<0.0001), montelukast (18%, 33%, 39%, P<0.0001), omalizumab (9%, 31%, 33%, P<0.0001), oral corticosteroids (10%, 2%, 3%, P=0.0012), and cyclosporine (1%, 3%, 4%, p=0.0233) was significantly different between groups. Conclusions A higher proportion of patients with CSU symptom resolution were prescribed H2 blockers, montelukast, or omalizumab at their final visit versus patients with ongoing CSU symptoms. Understanding the factors leading to CSU resolution may contribute to improving the quality of care for patients with CSU."

Clinical • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria